Martin Chasen MBChB, FCP(SA), MPhil(Pall Med)
Associate Professor
DFCM - Division of Palliative Care
Dr. Martin Chasen
Location
William Osler Health System - Brampton Civic Hospital
2100 Bovaird Drive East, Office N.5.027
Brampton, ON, L6R 3J7
Accepting
Graduate Students
Summer Students
Research Interests
Cancer Care, Family Caregivers, Palliative Care, Quality Improvement, Quality of Life/Satisfaction, Anorexia/Cachexia Syndrome, Survivorship

Current Appointments: 
    
Jul. 2015 - present Medical Director, Palliative Care, William Osler Health System - Brampton and Etobicoke, Toronto 
Dec. 2016 - present Regional Clinical Co- Lead, Physician for the Central West Palliative Care Network 
Feb. 2017 – present Clinical Lead, Research, William Osler Health System - Brampton and Etobicoke, Toronto 
April 2017 – present Site Lead, Residency program for Royal College Palliative Medicine Program, University of Toronto 
Aug 2017- present Affiliate Investigator, Bruyere Research Institute, Ottawa 
   
University Appointments: 
    
Apr.2019 - present Associate Professor, Department of Medicine, Faculty of Medicine, University of Toronto 
2017 - present Adjunct Professor, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Australia 
Aug. 2016 – present Associate Clinical Professor, Department of Family Medicine, Faculty of Health Sciences McMaster University 
Dec.2015 - present Associate Professor, Department of Family and Community Medicine, University of Toronto 
Jul. 2015 - present Adjunct Professor, Departments of Medicine, University of Ottawa 
2010- present Adjunct Professor, Departments of Medicine and Oncology, McGill University 
    
University Cross Appointments: 
    
Aug. 2016 – present Associate Clinical Professor, Department of Family Medicine, Faculty of Health Sciences McMaster University 
Dec.2015 - present Associate Professor, Department of Family and Community Medicine, University of Toronto 
    
Other: 

2016- present Regional Clinical Co- Lead, Physician for the Central West Palliative Care Network 
    
Qualifications, Certifications and Licenses: 
   
1983 MB ChB, General Practitioner, SA MEDICAL AND DENTAL COUNCIL 
1992 FCP (SA), Internal Medicine 
1994 FCP (SA), Medical Oncology 
1998 General Practitioner, GENERAL MEDICAL COUNCIL OF THE UNITED KINGDOM 
1999 Medical Oncologist, GENERAL MEDICAL COUNCIL OF THE UNITED KINGDOM 
2004 MPhil (Pall Care) Palliative Care 
2004 Restrictive Permit: Internal Medicine, Medical Oncology, COLLEGE DES MEDECINS DU QUEBEC 
2009 Medical Oncology, COLLEGE DES MEDECINS DU QUEBEC –Full Registration 
2014 Independent practice Medical Oncology COLLEGE OF PHYSICIANS AND SURGEONS OF ONTARIO 
2016 Independent practice Palliative Care COLLEGE OF PHYSICIANS AND SURGEONS OF ONTARIO 

Research/Teaching

Grants

Peer-Reviewed Grants:
    
2006 NCIC Sociobehavioural Cancer Research Network: Cancer Pain Classification Project: Pilot and Feasibility Phase ($45,000) (awarded) 
    
Sep 2007-08 Expanding the Role of Pre-operative Rehabilitation: The Impact of a Multidisciplinary Program of Improving Nutritional Reserve and Exercise Capacity on Post-operative Complications after Major Thoracic Cancer Surgery ($20,000) - Co-Investigator-Research Institute of the McGill University Health Centre (awarded) 
    
2007 Evaluation of a 12-week comprehensive exercise program following adjuvant therapy for breast cancer ($10,000)-Co-Investigator-Research Institute of the McGill University Health Centre (awarded) 
    
2007 Towards an understanding of cancer cachexia-Linking molecular mechanisms with novel treatment options ($2,000,000)-Co-Principal Investigator-Terry Fox Research Institute TFRI (Montreal) (awarded) 
    
2008 What is the Relationship between a Focussed Exercise Program and Cancer-Related Fatigue? Research Institute of the MUHC ($20,000): Research Institute’s Clinical Research Pilot Project Competition (awarded) 
    
2009- 2015 The Palliative Rehabilitation Programme: Enhancing Functioning, Appetite and Quality of Life in Cancer Patients ($120,000 / year); Principal Investigator- Martin Chasen; Ottawa Regional cancer Foundation (In collaboration with Bruyere foundation) (awarded) 
    
2010- 2015 The Value of EGG (Electrogastrogram) in Patients with the Anorexia / Cachexia syndrome ($20,000 / year); Principal Investigator - Bruyere foundation (awarded) 
    
2011-2012 Partners in Cancer Rehabilitation Research: Canada and Beyond ($23,542). Sara McEwen, Margaret Fitch, Martin Chasen, Mary Egan. Canadian Institutes of Health Research (CIHR) KPE-117820 (awarded) 
    
2012- 2016 The effect of Ginger (Zingiber officinale) in patients with the Cancer Anorexia Cachexia syndrome ($10,000 / year); Principal Investigator – Bruyere AMO Incentive Fund (awarded) 
    
2014-2019 Multimodal Exercise, Nutrition and Anti-inflammatory Treatment For Palliation of Cancer Cachexia: the MENAC ($373,422). Martin Chasen, Vickie Baracos, Thomas Jagoe ; Canadian Institutes of Health Research (CIHR) DC0190GP (awarded) 
    
2017- 2019 Perceptions of palliative care in the South Asian community ($4,967); Naheed Dosani, Ravi Bhargava, Gurwinder Gill, Martin Chasen, Sukhjeet Dhillon, Bonnie Keating; Department of Family Medicine- Pilot Project Funding: McMaster University (awarded) 
    
2017- 2019 The characterization of Gastric Myoelectrical Activity as measured by ElectroGastrography (EGG) in patients receiving renal replacement therapy ($20,000); Martin Chasen, Ravi Bhargava, Davender Wadehra, Bajinder Reen; In collaboration with WOHS Foundation (awarded) 
    
2018 - 2019 Remote Self-Reporting of Symptoms by Patients with a Palliative Care Designation (RELIEF) ($50,000). Principal Investigator- Martin Chasen, Centre for Aging Brain Health Innovation (awarded) 
     
2019 Use of an automated prospective clinical surveillance tool to drive screening for unmet palliative needs among patients in the final year of life (KT2019-04 Grant) ($224,000). Principal Investigator- Pete Wegier, James Downar, Martin Chasen et al., Canadian Frailty Network (awarded) 
    
Industrial Grants: 
    
2006 Phase II Study of Neoadjuvant Taxotere Cisplatinum and 5FU in Patients with Gastric or Gastroeosophageal Junction Adenocarcinoma 
  
2006-08 Co-Investigator: A Double-Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Orexigenic Therapy with delta-9-Tetrahydrocannabinol (THC) in Advanced Cancer Patients with Chemosensory Abnormalities 
    
2006-2010 Principal Investigator (research trial): A Phase 2, Open-Label, Multi-Center Study with AVRll8 in Anorectic Patients with Recurrent or Advanced Malignancies. Royal Victoria Hospital, McGill University 
    
2010- 2012 The Palliative Rehabilitation Programme: Enhancing Functioning, Appetite and Quality of Life in Cancer Patients ($12,000 / year); Principal investigator- Operational Grant: Valeant Pharmaceuticals. 
    
2010-2012 The Palliative Rehabilitation Programme: Enhancing Functioning, Appetite and Quality of Life in Cancer Patients ($10,000 / year); Principal investigator- Operational Grant: Bristol-Myers Squibb Canada Inc. 
    
2010- 2013 Principal Investigator (research trial): A Phase 2, Open-Label, Multi-Center Study with AVR / OHRll8 in Anorectic Patients with Recurrent or Advanced Malignancies. The Ottawa Hopsital, University of Ottawa 
    
2010-2013 The Palliative Rehabilitation Programme: Enhancing Functioning, Appetite and Quality of Life in Cancer Patients ($25,000 / year); Principal investigator- Operational Grant: Family Donation. 
    
2010- 2014 The Palliative Rehabilitation Programme: Enhancing Functioning, Appetite and Quality of Life in Cancer Patients ($50,000 / year); Principal investigator- Operational Grant: Pfizer Inc. 
    
2010-2014 Sam Karpman donation for Research ($5000/year) 
    
2010-14 Pfizer grant for Palliative Rehabilitation research ($35 000/ year for 4 Years) 
    
2010- to date The Palliative Rehabilitation Programme: Enhancing Functioning, Appetite and Quality of Life in Cancer Patients ($5,000 / year); Principal investigator- Operational Grant: Order of St. Lazarus of Jerusalem 
    
2012-14 A Randomized, Double-Blind, Phase 2 Safety Study of Cetuximab, Using ImClone versus Boehringer Ingelheim Manufacturing Processes, in Combination with Cisplatin or Carboplatin and 5-Fluorouracil in the First-Line Treatment of Patients with Locoregionally Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (Protocol I4E-MC-JXBD(b). Principle Investigator (In collaboration with Eli Lilly and Company, Indianapolis, Indiana USA) (Awarded) 
    
2017-19 Modified Palliative Rehabilitation Program –Principal Investigator – ($20,000.00): Operational Grant – William Osler Health System (Awarded) 
    
2017-19 Role of Ensure Enlive on appetite, calorie and protein intake, body composition and physical function in patients with advanced cancer receiving chemotherapy–Principal Investigator – ($62,960.75): Operational Grant – Abbott Canada Inc. (Awarded) 
    
2017-19 A Prospective, Observational Study Evaluating the Incidence of Nausea and Vomiting in Patients with Cancer Receiving Carboplatin-Based Therapy ($25,000); Martin Chasen, Henry Conter, Ravi Bhargava: The Medical Oncology Centre of Rosebank, South Africa (awarded) 

Publications and Awards

Recent Publications

1. Rapoport B, Chasen M, Gridelli C, Urban L, Modiano M, Schnadig I, Poma A, Arora S, Kansra V, Schwartzberg L, Navari R. Safety and Efficacy Assessment of Rolapitant for the Prevention of Chemotherapy‐Induced Nausea and Vomiting Following Administration of Cisplatin-Based Highly Emetogenic Chemotherapy in Cancer Patients in Two Randomised Phase 3 Trials. The Lancet Oncology, Volume 16, No. 9, p1079–1089, September 2015

2. M Chasen, N Dosani. Are patients receiving the right care in the right place at the right time?; Current Oncology, Vol. 22, No. 5, October 2015

3. Jose L Pereira, Martin R Chasen, Sean Molloy,Heidi Amernic, Michael D Brundage, Esther Green, Serena Kurkjian, Monika K Krzyzanowska, Wenonah Mahase, Omid Shabestari, Reena Tabing, Christopher A Klinger. Cancer Care Professionals' Attitudes toward Systematic Standardized Symptom Assessment and the Edmonton Symptom Assessment System (ESAS) Following Large-Scale Population-Based Implementation in Ontario (Canada). Journal of Pain and Symptom Management, 2016 4:51(4):662-672,e8

4. Andrea Feldstain, Sophie Lebel, Martin R Chasen. An interdisciplinary palliative rehabilitation intervention bolstering general self-efficacy to attenuate symptoms of depression in patients living with advanced cancer. Journal of Supportive Care in Cancer, Volume 24, Issue 1, pp 109-117, Jan. 2016

5. M Chasen, Rapoport B. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence. Future Oncology. 2016 Mar;12(6):763-78. doi: 10.2217/fon.16.11.

6. Rapoport B, Schwartzberg L, Chasen M, Powers D, Arora S, Navari R, Schnadig I. "Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy". European Journal of Cancer, vol 57, p23-30, April.2016.

7. Esther Green, Dora Yuen, Martin Chasen et al.Oncology Nurses’ Attitudes Toward the Edmonton Symptom Assessment System: Results From a Large Cancer Care Ontario Study; ONF 2017, 44(1), 116-125 DOI: 10.1188/17.ONF.116-125

8. John N Waldron; Bingshu E Chen; Eric Winquist; Jim R Wright; Abdenour Nabid; John H Hay; Jolie Ringash; Geoffrey Liu; Ana Johnson; George Shenouda; Chasen, Martin; Andrew Pearce; James B Butler; Stephen Breen; Eric Xueyu Chen; TJ FitzGerald; TJ Childs; Alexander Montenegro; Brian O'Sullivan; Wendy R Parulekar. Phase III Randomized Trial of Standard Fractionation Radiotherapy with Concurrent Cisplatin versus Accelerated Fractionation Radiotherapy with Panitumumab in Patients with Loco regionally Advanced Squamous Cell Carcinoma of the Head and Neck: Canadian Cancer Trials Group HN.6 Trial. Journal of Clinical Oncology (JCO), JCO/2016/677849; Oct.2016 (In Press)

9. Chasen M, Urban L, Schnadig I, Rapoport B, Powers D, Arora S, Navari R, Schwartzberg L, Gridelli C. Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Supportive Care in Cancer, Support Care Cancer (2017) 25:85–92

10. Jose Pereira, Martin Chasen. Early palliative care: taking ownership and creating the conditions. Current Oncology, Editorial; Vol. 23, No. 6, December 2016

11. Siu LL, Waldron JN, Chen BE, Winquist E, Wright JR, Nabid A, Hay JH, Ringash J, Liu G, Johnson A, Shenouda G, Chasen M, Pearce A, Butler JB, Breen S, Chen EX, FitzGerald TJ, Childs TJ, Montenegro A, O'Sullivan B, Parulekar WR. Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial. JAMA Oncol.;3(2):220-226. Doi:10.1001/jamaoncol.2016.4510; 2017

12. Andrea Feldstain, Sophie Lebel, Martin R Chasen. "The longitudinal course of depression symptomatology following a palliative rehabilitation program". Quality of Life Research; doi: 10.1007/s11136-017-1531-7. [Epub ahead of print] Feb 2017

13. Andrea Feldstain, Neil MacDonald, Ravi Bhargava, Martin Chasen. “Reported distress in patients living with advanced cancer: Changes pre-post interdisciplinary palliative rehabilitation”. Journal of Support Care Cancer. Volume 25, Issue 10, pp 3191–3197; October 2017

14. Martin Chasen. Who’s talking to who during transitions. Quality of Life in Oncology, Commentary: http://qualityoflife.elsevierresource.com/ ; March, 2017

15. Bernardo Rapoport, Matti Aapro; Martin Chasen; Jordan, Karin; Rudolph Navari; Ian Schnadig; Lee Schwartzberg. “Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations”. Drug Design, Development and Therapy. Volume:11 Pages 2621—2629, DOI https://doi.org/10.2147/DDDT.S133943; 2017

16. Martin Chasen, Sean Hollingshead, Henry Conter, Ravi Bhargava. “The Quality of Life of patients surviving cancer- Are we moving ahead?". Current Oncology, vol.24 (3); 2017

17. Rapoport B, Aapro M, Chasen M, Jordan K, Navari R, Schnadig I, Schwartzberg L. Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations. Drug Design, Development and Therapy:11 2621–2629; Sept 2017

18. Federico Bozzetti, Florian Strasser, Jann Arends, Carla Ripamonti, Martin Chasen et al. Cancer Cachexia in Adult Patients: ESMO Clinical Practice Guidelines, Special Article: ESMO (European Society for Medical Oncology). Annals of Oncology. Jan.2018 (InPress)

19. Santa Mina, D, Sabiston, CM, Au, D, Fong, A, Capozzi, LC, Langelier, D, Chasen, M, Chiarotto, J, Tomasone, J, Jones, JM, Chang, E, Culos-Reed, SN. “Connecting People with Cancer to Physical Activity and Exercise Programs: A Pathway to Create Accessibility and Engagement.” Current Oncology. 25(2):149-162; 2018

20. Rosenblum AM, Chasen MR. Palliative care: who is responsible? J Natl Compr Canc Netw:16(6):791–792; 2018

21. Glenn G Fletcher, Martin R. Chasen, Lynne Penton. “Guidelines on Management of Nausea and Vomiting or on Loss of Appetite/Anorexia/Cachexia in Cancer”. Evidence Summary SMG-2, A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO). https://www.cancercareontario.ca/en/guidelines-advice ; Jun.2018

22. Nicole Rutowski, Andrea Feldstain, Martin Chasen, Sophie Lebel, Brittany Elizabeth Mutsaers. With a little help from my friends: Social support in palliative rehabilitation. Current Oncology, Editorial; Vol., No., July 2018

23. Santa Mina, D, Langelier, D, Adams, SC, Alibhai, SMH, Chasen, M, Campbell, K, Oh, P, Jones, JM, Chang, E. “Exercise as a part of routine care”. Lancet Oncology. 19(9). PE433-E436.DOI:https://doi.org/10.1016/S1470-2045(18)30599-0 – Invited Publication; 2018

24. Shauna Daly, Andre Samson, Nick Gazzola, Katherine Moreau, Tara Tucker, Martin Chasen. Family Caregiver Experiences: A Case Study of Caregiving for an Advanced Cancer Patient Enrolled in a Palliative Rehabilitation Program With a little help from my friends: Social support in palliative rehabilitation. Journal of Pain and Symptom Management, Vol. 56, Issue 6, e90–e91; Dec.2018

25. Arminee Kazanjian, Jennifer Jones, Linda Carlson, Martin Chasen, Ravi Bhargava, David Langelier. Reflections on Cancer Rehabilitation and Survivorship in Canada: Observing ten years of evidence informed practice. Journal of Cancer Rehabilitation, J Cancer Rehabilitation; 2: 18-23 Apr. 2019

Honours and Awards

Distinctions and Research Awards:

 
1992 The Lennon Gold Medal, South African Society of Medical Oncology 
1993-1996 Aaron Beare Foundation Grant for Further Research in Hepatocellular Carcinoma 
1997 Best Presentation, South African Society of Medical Oncology 
2006 Research Institute of MUHC - Simone and Morris Fast Award for Oncology 
2007 Research Institute of MUHC - Simone and Morris Fast Award for Oncology 
2008 Research Institute of MUHC - Simone and Morris Fast Award for Oncology 
2009 Cancer Nutrition and Rehabilitation program received supra regional status by Sante et services sociaux Quebec” Programme Quebecois de luttre contre le cancer 
2009-2015 Scientist, Palliative Rehabilitation and Survivorship, Élisabeth Bruyère Research Institute and Ottawa Regional Cancer Foundation 
2010 National Institute of Health (NIH) - Award of Merit for service to NCI in developing and maintaining evidence based PDQ cancer information summaries for health professionals and the public. 
2013 Medical Director of ESMO recognised Integrated Oncology Centre (The Ottawa Hospital Cancer Centre) 
2015-2016 ESMO Faculty Member for Supportive and Palliative Care, European Society for Medical Oncology- Educational Committee 
2017 Elizabeth J Latimer Prize in Palliative Care, Mc Master University 
2017 Kay Blair Community Service Award, William Osler Health System 
2018 “Heroes in the Home” Caregiver Recognition Award, Central West Local Health Integration Network (CW-LHIN) 
2018 “Virtual Palliative Care” Leading Operational Practice Award in Home Based Palliative Care, Canadian Homecare Association (CHCA) 
2019 Medical lead for ESMO Designated Centre of Integrated Oncology and Palliative Care Brampton